Although initially hailed as a potential treatment for obesity and diabetes, the clinical applications of leptin have remained limited, owing at least in part to an incomplete understanding of the mechanism by which leptin regulates gene expression including that of key neuropeptides such as AGRP and NPY (16, 17). This evidence concerns the gene AGRP and obesity due to melanocortin 4 receptor deficiency.